Skip to main content
CTOS 2023 Main banner
Final Program


Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Hans Gelderblom, MD, PhD (he/him/his)

Medical Oncologist
Leiden University Medical Center
Leiden, Zuid-Holland, Netherlands

Prof Hans Gelderblom is chair of the department of medical oncology at the Leiden University Medical Center (LUMC) in the Netherlands and of the comprehensive regional cancer center (https://www.universiteitleiden.nl/en/staffmembers/hans-gelderblom#tab-1).

He is former chair of the the EORTC Soft Tissue and Bone Sarcoma Group. The LUMC is the (co)leading institution for the EU project Personalised Cancer Medicine for all EU citizens (https://www.matrix-fkb.no/en/pcm4eu/home) and implementation project PRIME-ROSE .

The LUMC is a specialised center in bone and soft tissue sarcoma, including GIST and also hosting the Dutch Bone Tumour Committee. Due to the close collaboration in the sarcoma team and vast clinical trial unit experience, the LUMC developed into one of the world leading institutes on the development of CSF-R1 inhibitors, such as vimseltinib, for diffuse type tenosynovial giant cell tumours, which is the subject of his oral presentation at CTOS 2023.

Disclosure information not submitted.

Presentation(s):

Email Hans